Objectives: To use health economic modeling techniques to quantify and compare the clinical and economic outcomes associated with the use of subcutaneous interferon beta-1a (scIFNβ 1a) vs. intramuscular interferon beta-1a (imIFNβ 1a) over 2 years in the management of relapsing forms of multiple sclerosis (MS) from a US health care payer perspective. MethOds: The 2-year decision analytic model w...

BACKGROUND In patients who present with clinically isolated syndromes suggestive of multiple sclerosis, interferon beta-1a is effective in delaying evolution to clinically definite disease and in reducing MRI-measured disease activity. We aimed to assess whether this drug can also reduce the rate of brain volume decrease in such patients enrolled in the ETOMS (early treatment of multiple sclero...

BACKGROUND Alemtuzumab is a humanised monoclonal antibody that depletes lymphocytes, causing long-term immunomodulation. In a 3-year, rater-blinded phase 2 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzumab reduced relapse rate and the risk of sustained accumulation of disability compared with subcutaneous interferon beta-1a, and the mean expa...

OBJECTIVE To investigate the value of Expanded Disability Status Scale (EDSS) worsening sustained for at least 6 months and other parameters as predictors for disability status. DESIGN Retrospective analysis of the Multiple Sclerosis Collaborative Research Group study data. SETTING The intramuscular interferon beta-1a pivotal trial was a double-blind, placebo-controlled phase 3 study. PAR...